Alnylam Licenses RSV Drug Rights to Cubist, Maintains Cash Guidance and Eye on Alliances

According to a Cubist official, partnering with Alnylam gives the company a new technological angle from which to approach the RSV field, but is not signal that it plans to jump into the RNAi drugs space.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.